Senator Shaheen Questions FDA Commissioner on COVID-19 Booster Access and Diabetes Care

COVID-19 Booster Shot Access

• ⚠️ Senator Shaheen expressed surprise at the FDA's decision to limit access to COVID-19 boosters, particularly for those under 65 and not high-risk.
• ❓ The FDA Commissioner explained the decision was based on a lack of clinical trial data supporting repeat booster strategies for healthy individuals, contrasting with previous years.
• 🌍 The FDA is adopting an age-stratified framework, aligning with countries like the UK and France, to move towards a more scientific approach to booster recommendations.
• ⏳ While specific timelines are not finalized, the FDA is encouraging vaccine manufacturers to present clinical trial data, with a reasonable timeframe anticipated before the fall.

Diabetes Care and Medical Innovations

• 💡 Senator Shaheen highlighted the personal significance of diabetes, sharing her experience with a granddaughter who has type one diabetes.
• 🔬 The discussion touched upon C-peptide as a potentially more accurate tool for measuring pancreatic function, with the FDA Commissioner agreeing to review its recognition as a validated surrogate endpoint.
• 📊 The senator urged for greater Congressional engagement in proposed changes to healthcare policies, citing concerns about decisions being made without sufficient public input or legislative involvement.

FDA's Evolving COVID-19 Strategy

• 📊 The FDA is moving away from a perceived